WAVE Life Sciences Ltd.
WVE
$6.99
-$0.42-5.67%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 103.75% | -14.98% | -7.06% | -4.42% | -37.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 103.75% | -14.98% | -7.06% | -4.42% | -37.29% |
| Cost of Revenue | 17.10% | 21.77% | 25.95% | 22.82% | 17.40% |
| Gross Profit | 31.54% | -161.52% | -216.51% | -207.59% | -129.98% |
| SG&A Expenses | 24.79% | 23.59% | 21.34% | 15.07% | 10.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.21% | 22.28% | 24.64% | 20.63% | 15.30% |
| Operating Income | 10.59% | -71.47% | -74.24% | -62.37% | -63.71% |
| Income Before Tax | 14.43% | -75.12% | -80.18% | -66.71% | -67.74% |
| Income Tax Expenses | -- | -- | -- | -- | -100.00% |
| Earnings from Continuing Operations | 14.43% | -76.74% | -82.16% | -68.67% | -67.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.43% | -76.74% | -82.16% | -68.67% | -67.73% |
| EBIT | 10.59% | -71.47% | -74.24% | -62.37% | -63.71% |
| EBITDA | 10.50% | -76.27% | -80.61% | -69.07% | -69.23% |
| EPS Basic | 33.84% | -51.76% | -57.17% | -42.17% | -28.24% |
| Normalized Basic EPS | 33.83% | -50.74% | -56.00% | -41.18% | -28.75% |
| EPS Diluted | 33.25% | -52.23% | -57.65% | -42.74% | -28.76% |
| Normalized Diluted EPS | 32.81% | -52.52% | -57.95% | -43.06% | -28.65% |
| Average Basic Shares Outstanding | 30.89% | 30.80% | 30.13% | 30.64% | 22.93% |
| Average Diluted Shares Outstanding | 33.05% | 32.81% | 32.25% | 32.90% | 22.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |